Compare KELYA & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | ELDN |
|---|---|---|
| Founded | 1946 | 2004 |
| Country | United States | United States |
| Employees | 4900 | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 300.3M |
| IPO Year | N/A | 2014 |
| Metric | KELYA | ELDN |
|---|---|---|
| Price | $11.94 | $3.60 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $15.00 | $8.50 |
| AVG Volume (30 Days) | 475.6K | ★ 963.9K |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ 30.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.98 | $1.35 |
| 52 Week High | $14.94 | $4.60 |
| Indicator | KELYA | ELDN |
|---|---|---|
| Relative Strength Index (RSI) | 68.86 | 48.91 |
| Support Level | $8.30 | $3.35 |
| Resistance Level | $12.01 | $4.09 |
| Average True Range (ATR) | 0.44 | 0.20 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 84.21 | 34.09 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Eledon Pharmaceuticals Inc is a clinical stage biotechnology company using immunology expertise in targeting the CD40 Ligand pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis. Its compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40L, a well-validated biological target that has broad therapeutic potential. It operates as one reportable segment, focused on the development of tegoprubart, to develop therapies to protect transplanted organs and prevent rejection, and to treat ALS.